These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 18676595)

  • 1. New insights into clinical response in schizophrenia: from dopamine D2 receptor occupancy to patients' quality of life.
    Goff DC
    Am J Psychiatry; 2008 Aug; 165(8):940-3. PubMed ID: 18676595
    [No Abstract]   [Full Text] [Related]  

  • 2. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
    Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
    Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of new antipsychotic medications: occupancy is not just antagonism.
    Grunder G; Carlsson A; Wong DF
    Arch Gen Psychiatry; 2003 Oct; 60(10):974-7. PubMed ID: 14557141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
    Gründer G; Kungel M; Ebrecht M; Göröcs T; Modell S
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S21-5. PubMed ID: 16508892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
    Kegeles LS; Slifstein M; Frankle WG; Xu X; Hackett E; Bae SA; Gonzales R; Kim JH; Alvarez B; Gil R; Laruelle M; Abi-Dargham A
    Neuropsychopharmacology; 2008 Dec; 33(13):3111-25. PubMed ID: 18418366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study.
    Gründer G; Fellows C; Janouschek H; Veselinovic T; Boy C; Bröcheler A; Kirschbaum KM; Hellmann S; Spreckelmeyer KM; Hiemke C; Rösch F; Schaefer WM; Vernaleken I
    Am J Psychiatry; 2008 Aug; 165(8):988-95. PubMed ID: 18381901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole in an animal model of chronic alcohol consumption and dopamine D₂ receptor occupancy in rats.
    Nirogi R; Kandikere V; Jayarajan P; Bhyrapuneni G; Saralaya R; Muddana N; Abraham R
    Am J Drug Alcohol Abuse; 2013 Mar; 39(2):72-9. PubMed ID: 23421566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Aripiprazole in the treatment of schizophrenia].
    Bridler R
    Praxis (Bern 1994); 2005 Jun; 94(23):975-7. PubMed ID: 16001540
    [No Abstract]   [Full Text] [Related]  

  • 9. Aripiprazole treatment causes extrapyramidal side effects but not prolactin elevation: a disconnect of the striatal D2 occupancy story: case report.
    Shim JC; You YS; Kelly DL
    J Clin Psychopharmacol; 2008 Jun; 28(3):353-4. PubMed ID: 18480699
    [No Abstract]   [Full Text] [Related]  

  • 10. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
    Tateno A; Arakawa R; Okumura M; Fukuta H; Honjo K; Ishihara K; Nakamura H; Kumita S; Okubo Y
    J Clin Psychopharmacol; 2013 Apr; 33(2):162-9. PubMed ID: 23422369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models.
    Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
    Int J Neuropsychopharmacol; 2011 Oct; 14(9):1165-78. PubMed ID: 21087552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors.
    Stahl SM
    J Clin Psychiatry; 2001 Nov; 62(11):841-2. PubMed ID: 11775041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial agonism and schizophrenia.
    Bolonna AA; Kerwin RW
    Br J Psychiatry; 2005 Jan; 186():7-10. PubMed ID: 15630117
    [No Abstract]   [Full Text] [Related]  

  • 14. Partial agonists in schizophrenia.
    Cousins DA; Young AH
    Br J Psychiatry; 2005 Apr; 186():354. PubMed ID: 15802697
    [No Abstract]   [Full Text] [Related]  

  • 15. Aripiprazole. Abilitat, OPC 14597.
    Drugs R D; 2002; 3(1):25-7. PubMed ID: 11881525
    [No Abstract]   [Full Text] [Related]  

  • 16. Aripiprazole: a review of its pharmacology and clinical use.
    Taylor DM
    Int J Clin Pract; 2003; 57(1):49-54. PubMed ID: 12587943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placental transfer of aripiprazole.
    Nguyen T; Teoh S; Hackett LP; Ilett K
    Aust N Z J Psychiatry; 2011 Jun; 45(6):500-1. PubMed ID: 21413838
    [No Abstract]   [Full Text] [Related]  

  • 18. Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5-HT2 receptor occupancy studies and clinical response.
    Nyberg S; Nakashima Y; Nordström AL; Halldin C; Farde L
    Br J Psychiatry Suppl; 1996 May; (29):40-4. PubMed ID: 8733822
    [No Abstract]   [Full Text] [Related]  

  • 19. Striatal Dopamine D2 Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia.
    Nishibe H; Tateno A; Sakayori T; Yamamoto M; Kim W; Kakuyama H; Okubo Y
    Int J Neuropsychopharmacol; 2021 Feb; 24(2):108-117. PubMed ID: 32936897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perinatal use of aripiprazole: a case report.
    Watanabe N; Kasahara M; Sugibayashi R; Nakamura T; Nakajima K; Watanabe O; Murashima A
    J Clin Psychopharmacol; 2011 Jun; 31(3):377-9. PubMed ID: 21532364
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.